EP3337508A4 - Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies - Google Patents
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies Download PDFInfo
- Publication number
- EP3337508A4 EP3337508A4 EP16839842.8A EP16839842A EP3337508A4 EP 3337508 A4 EP3337508 A4 EP 3337508A4 EP 16839842 A EP16839842 A EP 16839842A EP 3337508 A4 EP3337508 A4 EP 3337508A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hla
- treatment
- monoclonal antibody
- hematologic malignancies
- subcutaneous anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562208128P | 2015-08-21 | 2015-08-21 | |
US14/876,200 US9683050B2 (en) | 2011-05-02 | 2015-10-06 | Stable compositions of high-concentration allotype-selected antibodies for small-volume administration |
US201562262692P | 2015-12-03 | 2015-12-03 | |
PCT/US2016/047483 WO2017034906A1 (en) | 2015-08-21 | 2016-08-18 | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3337508A1 EP3337508A1 (en) | 2018-06-27 |
EP3337508A4 true EP3337508A4 (en) | 2019-04-03 |
Family
ID=58100864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16839842.8A Pending EP3337508A4 (en) | 2015-08-21 | 2016-08-18 | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3337508A4 (en) |
CA (1) | CA2987644A1 (en) |
WO (1) | WO2017034906A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3471761A2 (en) | 2016-06-21 | 2019-04-24 | University Of Oslo | Hla binding vaccine moieties and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012151199A1 (en) * | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69829891T2 (en) * | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF antibody |
AU2006218454B2 (en) * | 2005-03-03 | 2011-11-17 | Immunomedics, Inc. | Humanized L243 antibodies |
-
2016
- 2016-08-18 CA CA2987644A patent/CA2987644A1/en active Pending
- 2016-08-18 EP EP16839842.8A patent/EP3337508A4/en active Pending
- 2016-08-18 WO PCT/US2016/047483 patent/WO2017034906A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012151199A1 (en) * | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
Non-Patent Citations (7)
Title |
---|
ANONYMOUS: "Archive History for NCT01728207: Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL.", 11 March 2015 (2015-03-11), XP055560263, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT01728207?V_4=View#StudyPageTop> [retrieved on 20190221] * |
DEBORAH M STEPHENS ET AL: "Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies | Blood Journal", BLOOD, 3 December 2015 (2015-12-03), XP055559444, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/126/23/2740?sso-checked=true> [retrieved on 20190220] * |
HOYER B F ET AL: "Biologics therapy for systemic lupus erythematosus", ZEITSCHRIFT FÜR RHEUMATOLOGIE, SPRINGER, DE, vol. 74, no. 3, 9 April 2015 (2015-04-09), pages 206 - 214, XP035478732, ISSN: 0340-1855, [retrieved on 20150409], DOI: 10.1007/S00393-014-1458-0 * |
See also references of WO2017034906A1 * |
THOMAS M CARDILLO ET AL: "Abstract 587: Superior anti-tumor effects of an anti-HLA-DR IgG4 antibody, IMMU-114, in chronic and acute lymphocytic leukemia (CLL and ALL): Comparison to anti-CD20 therapy, chemotherapy, or combined with kinase inhibitors", CANCER RESEARCH, 1 July 2016 (2016-07-01), XP055560255, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/76/14_Supplement/587> [retrieved on 20190221] * |
THOMAS S. LIN ET AL: "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia", LEUKEMIA AND LYMPHOMA., vol. 50, no. 12, 19 December 2009 (2009-12-19), US, pages 1958 - 1963, XP055415743, ISSN: 1042-8194, DOI: 10.3109/10428190903186486 * |
ZIV ROSMAN ET AL: "Biologic therapy for autoimmune diseases: an update", BMC MEDICINE, vol. 11, no. 1, 1 December 2013 (2013-12-01), XP055560340, DOI: 10.1186/1741-7015-11-88 * |
Also Published As
Publication number | Publication date |
---|---|
WO2017034906A1 (en) | 2017-03-02 |
CA2987644A1 (en) | 2017-03-02 |
EP3337508A1 (en) | 2018-06-27 |
WO2017034906A8 (en) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1245134A1 (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
IL265755A (en) | Chimeric antigen receptors for the treatment of cancer | |
HK1252272A1 (en) | Methods of treating cancer using anti-ox40 antibodies | |
EP3383914A4 (en) | Anti-ox40 antibodies and methods of use thereof | |
EP3515478A4 (en) | Antibodies for siglec-15 and methods of use thereof | |
EP3387442A4 (en) | Humanized anti-cd73 antibodies | |
IL264674B1 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
EP3204422A4 (en) | Humanized anti-ox40 antibodies and uses thereof | |
EP3472200A4 (en) | Anti-myostatin antibodies and methods of use | |
EP3110440A4 (en) | Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia | |
EP3380524A4 (en) | Humanized anti-cll-1 antibodies | |
EP3532489A4 (en) | Neutralizing anti-tl1a monoclonal antibodies | |
IL248402A0 (en) | Humanized antibodies against ceacam1 | |
EP3394098A4 (en) | Anti-myostatin antibodies and methods of use | |
EP3645040A4 (en) | Use of anti-fam19a5 antibodies for treating cancers | |
EP3280440A4 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
EP3191128A4 (en) | Uses of anti-her3 antibodies for treating cancer | |
EP3383497A4 (en) | Novel antibodies for the treatment of cancers | |
EP3131581A4 (en) | Humanized anti-tf-antigen antibodies | |
EP3103811A4 (en) | Anti-tissue factor monoclonal antibody | |
EP3291837A4 (en) | Monoclonal antibody cocktails for treatment of ebola infections | |
EP3092002A4 (en) | Method of purifying monoclonal antibodies | |
EP3350217A4 (en) | Highly potent monoclonal antibodies to angiogenic factors | |
EP3183002A4 (en) | Monoclonal antibodies for treatment of microbial infections | |
EP3209686A4 (en) | Monoclonal anti-gpc-1 antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180320 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190301 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101AFI20190225BHEP Ipc: C07K 16/28 20060101ALI20190225BHEP Ipc: A61K 51/10 20060101ALI20190225BHEP Ipc: C07K 16/46 20060101ALI20190225BHEP Ipc: C07K 16/30 20060101ALI20190225BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200221 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |